MTOR and tuberous sclerosis: Among the PI3K inhibitors LY is a unique drug that inhibits mTOR signaling, such as rapamycin, and has been approved by the US Food and Drug Administration (FDA) for immunosuppressive and antiproliferative treatments for several diseases, such as tuberous sclerosis, psoriasis, and malignancy 24.